

(Original in Japanese)

To whom it may concern,

PharmaBio Corporation (Headquarter: Nagoya, Aichi; President and CEO: Hitoshi Kusano; hereinafter "PharmaBio") and ROHTO Pharmaceutical Co., Ltd. (Headquarter: Osaka City; President: Masashi Sugimoto; hereinafter "Rohto Pharmaceutical") have entered into a joint research agreement, aimed at carrying out the collaborative research on brand-new cell sheets by using PharmaBio's cell sheet manufacturing technology and Rohto Pharmaceutical's cells and culture media.



PharmaBio has developed a human (allogenic) subcutaneous adipose tissue derived mesenchymal stem cell sheet, one of PharmaBio's regenerative medicine products, by using its own unique technology to manufacture a cell sheet composed only of extracellular matrix components that the cells themselves produce and entered the clinical trial phase on patients suffering from myopic chorioretinal atrophy (Phase I/IIa clinical trial) for the time being.

Rohto Pharmaceutical has proceeded with the developments of cell preparations composed of human adipose tissue derived mesenchymal stem cells and serum free media bringing out the capability of adipose tissue derived mesenchymal stem cells, as well.

At this joint research, PharmaBio will develop brand-new cell sheets with Rohto Pharmaceutical's cells and serum free media by the cell sheet manufacturing technology and perform characteristic analysis of the developed cell sheets.

Rohto Pharmaceutical and PharmaBio will aim at the further progress of the cell sheet technology and the expansion of their clinical applications at this joint research.

It is expected that the joint research, which is aimed at the improvement of patients' QOL through most advanced medical technology and innovative approach, will become the important step for results of both companies' R&D activities over years to bear fruit.

【About PharmaBio Corporation】

Ever since established in October 2010, PharmaBio's main business is development of regenerative medicine products, development of manufacturing processes and contract manufacturing of cellular pharmaceuticals, and contract testing and inspection services such as cellular microbiological safety testing. PharmaBio started contract manufacturing business of regenerative medicine products ahead of other companies in 2011 and have been providing GMP/GCTP compliant services to global companies and others. Based on its solid manufacturing knowledge, PharmaBio is engaged in the development of new regenerative medicine products as well as high quality contract manufacturing services.

PharmaBio Corporation: <https://www.pharmabio.co.jp/en/index.html>

【About ROHTO Pharmaceutical Co., Ltd.】

In 1899, ROHTO Pharmaceutical Co., Ltd. was founded as started sales of "Ikatsu," a gastrointestinal medicine, to help the increasing number of people suffering from stomach diseases, which was becoming a health issue at the time. Since then, "health" has been Rohto's core value and we have been expanding our businesses from our core area of health & beauty centered on over-the counter (OTC) drugs and skincare products to functional foods, primary industries such as agriculture and food businesses such as restaurants, and recently regenerative medicine as well by promoting cutting edge life science research.

ROHTO Pharmaceutical Co., Ltd. : <https://www.rohto.co.jp/global/>

【Please contact below for any question】

PharmaBio Corporation

E-mail : ir_admin@pharmabio.co.jp

ROHTO Pharmaceutical Co., Ltd.

E-mail : pr@rohto.co.jp